Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PTCT logo PTCT
Upturn stock ratingUpturn stock rating
PTCT logo

PTC Therapeutics Inc (PTCT)

Upturn stock ratingUpturn stock rating
$49.52
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/10/2025: PTCT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

16 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $62.81

1 Year Target Price $62.81

Analysts Price Target For last 52 week
$62.81 Target price
52w Low $29.02
Current$49.52
52w High $58.38

Analysis of Past Performance

Type Stock
Historic Profit -7.42%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/10/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.92B USD
Price to earnings Ratio 7.61
1Y Target Price 62.81
Price to earnings Ratio 7.61
1Y Target Price 62.81
Volume (30-day avg) 16
Beta 0.51
52 Weeks Range 29.02 - 58.38
Updated Date 07/10/2025
52 Weeks Range 29.02 - 58.38
Updated Date 07/10/2025
Dividends yield (FY) -
Basic EPS (TTM) 6.51

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 33.56%
Operating Margin (TTM) 82.43%

Management Effectiveness

Return on Assets (TTM) 24.42%
Return on Equity (TTM) -7740.12%

Valuation

Trailing PE 7.61
Forward PE 6.05
Enterprise Value 2225421106
Price to Sales(TTM) 2.21
Enterprise Value 2225421106
Price to Sales(TTM) 2.21
Enterprise Value to Revenue 1.26
Enterprise Value to EBITDA 2.65
Shares Outstanding 79257000
Shares Floating 64407424
Shares Outstanding 79257000
Shares Floating 64407424
Percent Insiders 2.4
Percent Institutions 101.06

ai summary icon Upturn AI SWOT

PTC Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

PTC Therapeutics, Inc. was founded in 1998. It is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered drugs targeting post-transcriptional control processes. They have grown from a research-focused entity to a commercial-stage company with multiple marketed products.

business area logo Core Business Areas

  • Rare Diseases: Development and commercialization of therapies for rare diseases, with a focus on genetic disorders. Examples include Duchenne muscular dystrophy and spinal muscular atrophy.
  • Oncology: Research and development of treatments for various types of cancer.

leadership logo Leadership and Structure

The CEO of PTC Therapeutics is Matthew B. Klein. The organizational structure includes research, development, commercial, and administrative departments. The board of directors provides oversight and strategic guidance.

Top Products and Market Share

overview logo Key Offerings

  • Translarna (ataluren): Translarna is an orally available small-molecule drug marketed for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged 2 years and older. Market share data is difficult to obtain precisely, but PTC is a key player. Competitors include Sarepta Therapeutics (gene therapy based treatments) and steroids (generic, but provides some relief from the symptoms of DMD).
  • Emflaza (deflazacort): Emflaza is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD). Acquired from Marathon Pharmaceuticals. Market share data is difficult to obtain precisely. Competitors include other steroids (generic). Revenue is significant, but being challenged with more targeted approaches.
  • Evrysdi (risdiplam): PTC Therapeutics receives royalties from Roche on global sales of Evrysdi for spinal muscular atrophy (SMA). Evrysdi is the leading oral treatment for SMA. Other competitors include Novartis' Zolgensma and Biogen's Spinraza. This product does not directly add to PTC's revenue beyond royalty payments.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. The rare disease segment is growing due to increased awareness and orphan drug designation incentives.

Positioning

PTC Therapeutics is positioned as a company focused on developing innovative therapies for rare diseases. Their competitive advantages include their expertise in RNA biology and their established commercial infrastructure.

Total Addressable Market (TAM)

The total addressable market (TAM) for rare disease therapeutics is estimated to be hundreds of billions of dollars globally and is expanding rapidly. PTC Therapeutics is positioned to capture a significant portion of this TAM through their existing product portfolio and pipeline.

Upturn SWOT Analysis

Strengths

  • Established commercial infrastructure
  • Expertise in RNA biology
  • Diverse pipeline of product candidates
  • Royalties from Evrysdi sales

Weaknesses

  • High operating expenses
  • Reliance on key products
  • Regulatory challenges
  • Competition from larger pharmaceutical companies

Opportunities

  • Expansion into new therapeutic areas
  • Acquisition of complementary assets
  • Partnerships with other pharmaceutical companies
  • Increased awareness and diagnosis of rare diseases

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Generic competition
  • Pricing pressures

Competitors and Market Share

competitor logo Key Competitors

  • SRPT
  • VRTX
  • BIIB

Competitive Landscape

PTC Therapeutics faces competition from larger pharmaceutical companies with greater resources. However, PTC's focus on RNA biology and rare diseases gives it a competitive advantage in certain areas. The landscape is constantly evolving due to scientific and clinical advances.

Major Acquisitions

BioElectron Technology Corporation

  • Year: 2023
  • Acquisition Price (USD millions): 240
  • Strategic Rationale: Expand pipeline to include novel preclinical assets for mitochondrial diseases and other disorders.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by the commercialization of Translarna and Emflaza, as well as royalties from Evrysdi. Growth is tied to regulatory approval and reimbursement in different countries. The success of new drug candidates is critical to future growth.

Future Projections: Future growth projections depend on the success of clinical trials, regulatory approvals, and market penetration. Analyst estimates vary but generally project continued revenue growth. Specific projections should be obtained from financial news sources.

Recent Initiatives: Recent initiatives include advancing pipeline programs, expanding into new geographic markets, and strategic collaborations.

Summary

PTC Therapeutics is a biopharmaceutical company focused on rare diseases and oncology with established products and royalty streams. While their expertise in RNA biology and focus on rare diseases provide a competitive edge, high operating expenses and reliance on key products pose challenges. The company needs to expand its pipeline and navigate regulatory hurdles successfully to achieve sustainable growth. Success also depends on the competition from pharmaceutical companies with greater resources.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • PTC Therapeutics Investor Relations
  • SEC Filings
  • Industry Reports
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly. Consult with a financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About PTC Therapeutics Inc

Exchange NASDAQ
Headquaters Warren, NJ, United States
IPO Launch date 2013-06-20
CEO & Director Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Sector Healthcare
Industry Biotechnology
Full time employees 939
Full time employees 939

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.